Pages that link to "Q30577613"
Jump to navigation
Jump to search
The following pages link to Androgen receptor splice variants determine taxane sensitivity in prostate cancer (Q30577613):
Displaying 50 items.
- Splice Variants of Androgen Receptor and Prostate Cancer (Q26740592) (← links)
- A sting in the tail: the N-terminal domain of the androgen receptor as a drug target (Q26747094) (← links)
- Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice (Q26748538) (← links)
- When Prostate Cancer Circulates in the Bloodstream (Q26768470) (← links)
- Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer (Q26795625) (← links)
- Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies (Q26796704) (← links)
- Emerging data on androgen receptor splice variants in prostate cancer (Q28077830) (← links)
- Using circulating tumor cells to inform on prostate cancer biology and clinical utility (Q28083261) (← links)
- Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression (Q28117805) (← links)
- Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer (Q28607383) (← links)
- Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins (Q30244818) (← links)
- The link between androgen receptor splice variants and castration-resistant prostate cancer (Q30618562) (← links)
- Single cell dynamic phenotyping (Q30818964) (← links)
- CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration. (Q33873147) (← links)
- Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. (Q34108738) (← links)
- Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (Q34250350) (← links)
- Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. (Q34714945) (← links)
- Novel actions of next-generation taxanes benefit advanced stages of prostate cancer (Q35099127) (← links)
- N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy (Q35611451) (← links)
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (Q35956276) (← links)
- Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer (Q36004694) (← links)
- Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents (Q36414184) (← links)
- Androgen pathway resistance in prostate cancer and therapeutic implications (Q36416370) (← links)
- Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer (Q36586089) (← links)
- Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion? (Q37013311) (← links)
- Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies (Q37210010) (← links)
- Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain (Q37691775) (← links)
- Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer (Q37737611) (← links)
- Targeting the androgen receptor in prostate cancer (Q38217060) (← links)
- Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. (Q38298274) (← links)
- Switching and withdrawing hormonal agents for castration-resistant prostate cancer. (Q38309205) (← links)
- Leading causes of castration-resistant prostate cancer (Q38341864) (← links)
- Are androgen receptor variants a substitute for the full-length receptor? (Q38350089) (← links)
- Overview on the complexity of androgen receptor-targeted therapy for prostate cancer (Q38364166) (← links)
- The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer (Q38374417) (← links)
- Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment (Q38384489) (← links)
- Shaping of interphase chromosomes by the microtubule network. (Q38514865) (← links)
- Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. (Q38530028) (← links)
- Androgen receptor aberrations in the era of abiraterone and enzalutamide (Q38534949) (← links)
- Chemotherapy in Prostate Cancer (Q38555599) (← links)
- Novel agents for castration-resistant prostate cancer: Early experience and beyond (Q38574684) (← links)
- Allosteric alterations in the androgen receptor and activity in prostate cancer. (Q38625010) (← links)
- Patient-derived xenografts as in vivo models for research in urological malignancies (Q38714374) (← links)
- Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance (Q38743584) (← links)
- Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. (Q38832738) (← links)
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting (Q38835693) (← links)
- Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. (Q38865487) (← links)
- NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer (Q38865962) (← links)
- Androgen receptor variation affects prostate cancer progression and drug resistance (Q38977288) (← links)
- The promise of circulating tumor cells for precision cancer therapy (Q39031157) (← links)